Perinatal mortality · pregnant women
Vitamin A alone showed no clear difference in perinatal mortality compared with placebo or no treatment (high certainty).
1 finding from 1 review
Maternal anaemia · pregnant women
Vitamin A alone probably leads to lower maternal anaemia compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Maternal infection · pregnant women
Vitamin A alone may leads to lower maternal clinical infection compared with placebo or no treatment (low certainty).
1 finding from 1 review
Intervention not reported
Maternal mortality · Pregnant women
1 finding from 1 review
Intervention not reported
Perinatal mortality · Pregnant women
The intervention showed no clear difference in perinatal mortality (low certainty).
1 finding from 1 review
Intervention not reported
Maternal anaemia · Pregnant women
The intervention showed no clear difference in maternal anaemia (low certainty).
1 finding from 1 review
Intervention not reported
Maternal clinical infection · Pregnant women
The intervention showed no clear difference in maternal clinical infection (low certainty).
1 finding from 1 review
Recurrent pyelonephritis · pregnant women with a history of one or more UTI before or during pregnancy
It is very uncertain whether nitrofurantoin and close surveillance changes recurrent pyelonephritis compared with close surveillance alone (very low certainty).
1 finding from 1 review
Recurrent UTI (cystitis) · pregnant women with a history of one or more UTI before or during pregnancy
It is very uncertain whether nitrofurantoin and close surveillance changes recurrent UTI (cystitis) compared with close surveillance alone (very low certainty).
1 finding from 1 review
Birthweight < 2500 (g) · pregnant women with a history of one or more UTI before or during pregnancy
It is very uncertain whether nitrofurantoin and close surveillance changes birthweight < 2500 (g) compared with close surveillance alone (very low certainty).
1 finding from 1 review
Birthweight (g) · pregnant women with a history of one or more UTI before or during pregnancy
1 finding from 1 review
Apgar score less than 7 at 5 minutes · pregnant women with a history of one or more UTI before or during pregnancy
It is very uncertain whether nitrofurantoin and close surveillance changes five‐minute Apgar score < seven compared with close surveillance alone (very low certainty).
1 finding from 1 review
Miscarriage · pregnant women with a history of one or more UTI before or during pregnancy
It is very uncertain whether nitrofurantoin and close surveillance changes miscarriages compared with close surveillance alone (very low certainty).
1 finding from 1 review
Maternal death · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in maternal death compared with control (moderate certainty).
1 finding from 1 review
Infant death (up to 175 days) · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in infant death (up to 175 days) compared with control (moderate certainty).
1 finding from 1 review
Perinatal death (stillbirth + death in first week of life) · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in perinatal death (stillbirth + death in first week of life) compared with control (moderate certainty).
1 finding from 1 review
Any respiratory illness in women · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in any respiratory illness in women compared with control (high certainty).
1 finding from 1 review
Any respiratory illness in infants · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in any respiratory illness in infants compared with control (high certainty).
1 finding from 1 review
Maternal hospitalisation for any infection · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in maternal hospitalisation for any infection compared with control (moderate certainty).
1 finding from 1 review
Neonatal hospitalisation due to sepsis within 28 days of birth · Pregnant women aged 18 to 38 years and an estimated gestation of 20 to 36 weeks.
Viral influenza vaccine showed no clear difference in neonatal hospitalisation due to sepsis within 28 days of birth compared with control (moderate certainty).
1 finding from 1 review